Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

401. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group.

Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1999 PedsCCM Evidence-Based Journal Club

402. A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock

A randomized and controlled trial of the effect of treatment aimed at maximizing oxygen delivery in patients with severe sepsis or septic shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1999 PedsCCM Evidence-Based Journal Club

403. Impact of immunomodulating therapy on morbidity in patients with severe sepsis.

Impact of immunomodulating therapy on morbidity in patients with severe sepsis. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1999 PedsCCM Evidence-Based Journal Club

404. Effects of ibuprofen on the physiology and survival of hypothermic sepsis

Effects of ibuprofen on the physiology and survival of hypothermic sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1999 PedsCCM Evidence-Based Journal Club

405. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. (Abstract)

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. In patients with sepsis the production of arachidonic acid metabolites by cyclooxygenase increases, but the pathophysiologic role of these prostaglandins is unclear. In animal models, inhibition of cyclooxygenase by treatment with ibuprofen before the onset of sepsis reduces physiologic abnormalities and improves survival. In pilot studies of patients with sepsis, treatment (...) with ibuprofen led to improvements in gas exchange and airway mechanics.From October 1989 to March 1995, we conducted a randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (10 mg per kilogram of body weight [maximal dose, 800 mg], given every six hours for eight doses) in 455 patients who had sepsis, defined as fever, tachycardia, tachypnea, and acute failure of at least one organ system.In the ibuprofen group, but not the placebo group, there were significant declines in urinary

1997 NEJM Controlled trial quality: predicted high

406. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. (Abstract)

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic inflammatory response syndrome (SIRS) and presumed sepsis.Multicenter, randomized, placebo-controlled, double (...) with SIRS and gram-negative sepsis; however, additional studies would be required to prove this.

1997 JAMA Controlled trial quality: predicted high

407. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. (Abstract)

p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. To evaluate the safety and efficacy of p55 tumor necrosis factor receptor fusion protein, a recombinant chimeric protein of human p55 (type I) tumor necrosis factor receptor (CD120a) extracellular domain and IgG1 sequences (referred to as p55-IgG), in the treatment of patients with severe sepsis or septic (...) shock.Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial.Forty-four community and university-affiliated hospitals in the United States and Europe.There were 498 patients enrolled in this clinical trial.Patients prospectively stratified within each site into refractory shock or severe sepsis groups were randomized to receive a single infusion of p55-IgG, 0.083 mg/kg, 0.042 mg/kg, or 0.008 mg/kg, or placebo. Patients received standard aggressive medical/surgical care during

1997 JAMA Controlled trial quality: predicted high

408. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis

Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Jenson H B, Pollock B H Authors' objectives To determine the effectiveness of intravenous immune globulin (IVIG) in the prevention and treatment of neonatal (...) sepsis. Searching MEDLINE (no dates given) was searched for English language papers plus identification of studies by "personal knowledge". Study selection Study designs of evaluations included in the review Peer-reviewed, prospective randomised trials including a concurrent control group receiving either placebo or no IVIG treatment were eligible for inclusion. IVIG administration had to be given shortly after birth for prophylaxis, or on clinical diagnosis of sepsis for treatment. Specific

1997 DARE.

409. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. (Abstract)

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. A recombinant, soluble fusion protein that is a dimer of an extracellular portion of the human tumor necrosis factor (TNF) receptor and the Fc portion of IgG1 (TNFR:Fc) binds and neutralizes TNF-alpha and prevents death in animal models of bacteremia and endotoxemia.To evaluate the safety and efficacy of TNFR:Fc in the treatment of septic shock, we conducted

1996 NEJM Controlled trial quality: predicted high

410. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. (Abstract)

Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. Patients with acute respiratory distress syndrome (ARDS) have a deficiency of surfactant. Surfactant replacement improves physiologic function in such patients, and preliminary data suggest that it may improve survival.We conducted a prospective, multicenter, double-blind, randomized, placebo-controlled trial involving 725 patients with sepsis (...) analyzed according to APACHE III score, cause of death, time of onset and severity of ARDS, presence or absence of documented sepsis, underlying disease, whether or not there was a do-not-resuscitate order, and medical center. Increased secretions were significantly more frequent in the surfactant group; the rates of other complications were similar in the two groups.The continuous administration of aerosolized synthetic surfactant to patients with sepsis-induced ARDS had no significant effect on 30

1996 NEJM Controlled trial quality: predicted high

411. Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study. (Abstract)

Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study. To evaluate the effect of catheter tunneling on internal jugular catheter-related sepsis in critically ill patients.A prospective randomized controlled study involving 3 intensive care units (ICUs), stratified by number of catheter lumina (1 or 2) and center.The 10-bed medical-surgical and 10-bed surgical ICUs at Saint Joseph Hospital and 8-bed (...) surgical ICU at Clinique de la Défense, Paris, France.Every patient older than 18 years admitted to the ICUs between March 1, 1993, and July 17,1996, who required a jugular venous catheter for more than 48 hours.Random allocation to tunneled or nontunneled catheters.Times to occurrence of systemic catheter-related sepsis, catheter-related septicemia, or a quantitative catheter-tip culture with a cutoff of 103 colony-forming units per milliliter.A total of 241 patients were randomized. Ten patients

1996 JAMA Controlled trial quality: uncertain

412. Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994

Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994 Trotter C W Authors' objectives To evaluate methods of reducing catheter-related sepsis (CRS) in high-risk neonates. Searching MEDLINE, CINAHL (...) on the methods of this review. Literature searches were performed from 1990 onwards as the author states that she had previously reviewed literature published prior to 1990; however, no reference for this is provided. Implications of the review for practice and research There is a need for randomised controlled trials of methods to reduce CRS. Bibliographic details Trotter C W. Percutaneous central venous catheter-related sepsis in the neonate: an analysis of the literature from 1990 to 1994. Neonatal

1996 DARE.

413. Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis

Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1996 PedsCCM Evidence-Based Journal Club

414. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. (Abstract)

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. To evaluate the efficacy and safety of anti-tumor necrosis factor alpha monoclonal antibody (TNF-alpha MAb) in the treatment of patients with sepsis syndrome.Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial.A total of 31 hospitals in the United (...) States and Canada.There were 994 patients with sepsis syndrome enrolled in this clinical trial, and 971 patients were infused with the study drug.Patients were prospectively stratified into shock or nonshock groups and then randomized to receive a single infusion of 15 mg/kg of TNF-alpha MAb, 7.5 mg/kg of TNF-alpha MAb, or placebo. Patients received standard aggressive medical and surgical care during the 28-day postinfusion period.Twenty-eight-day all-cause mortality.The distribution of variables

1995 JAMA Controlled trial quality: predicted high

415. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature

Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature Cronin L, Cook D J, Carlet J, Heyland D K, King D, Lansang M A, Fisher C J Authors' objectives To determine the effect of corticosteroid therapy on morbidity and mortality in patients with sepsis. Searching MEDLINE (...) and EMBASE were searched from 1966 to 1993 using the following MeSH terms: 'sepsis' and 'steroids' or 'corticosteroids', and 'septic shock and 'steroids' or 'corticosteroids'. The Science Citation Index was searched using the terms 'sepsis' and (explode) 'corticosteroid', and 'septic shock' and (explode) 'corticosteroid'. Index Medicus was handsearched from 1951 onwardusing the terms 'corticosteroids', 'steroids', 'sepsis' and 'septic shock'. Personal files, reference lists of relevant primary and review

1995 DARE.

416. Steroid controversy in sepsis and septic shock: a meta-analysis

Steroid controversy in sepsis and septic shock: a meta-analysis Steroid controversy in sepsis and septic shock: a meta-analysis Steroid controversy in sepsis and septic shock: a meta-analysis Lefering R, Neugebauer E A Authors' objectives To conduct a meta-analysis to asses the clinical evidence for the use of corticosteroids on patients with septic shock, and to evaluate treatment effects in specific subgroups of patients. Searching MEDLINE was searched from 1966 to 1992. The authors' own (...) literature file, and references in trial reports and review articles, were also examined. Experts in the field of sepsis research were contacted for additional material. Study selection Study designs of evaluations included in the review Prospective randomised controlled trials (RCTs), which evaluated the effectiveness of corticosteroids in the management of septic shock, were included if they fulfilled the following criteria: a primary intention to assess the effectiveness of corticosteroids, a control

1995 DARE.

417. Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review

Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review Accuracy of leukocyte indices and C-reactive protein for diagnosis of neonatal sepsis: a critical review Da Silva O, Ohlsson A, Kenyon C Authors' objectives To evaluate the accuracy of C-reactive protein (CRP) and leukocyte indices in the diagnosis of infants suspected of having (...) septicaemia in a neonatal intensive care setting. Searching EMBASE and MEDLINE were searched from 1988 and 1966, respectively, to May 1994 using the following search terms: 'infant', 'new-born', 'C-reactive protein', 'leukocyte count', and 'sepsis' or 'septicaemia' or 'infection'. The bibliographies of primary and review articles were also searched, as were the authors' personal files. No language restrictions were applied. Study selection Study designs of evaluations included in the review No inclusion

1995 DARE.

418. The influence of clinical study design on cost-effectiveness projections for the treatment of Gram-negative sepsis with human anti-endotoxin antibody

The influence of clinical study design on cost-effectiveness projections for the treatment of Gram-negative sepsis with human anti-endotoxin antibody The influence of clinical study design on cost-effectiveness projections for the treatment of Gram-negative sepsis with human anti-endotoxin antibody The influence of clinical study design on cost-effectiveness projections for the treatment of Gram-negative sepsis with human anti-endotoxin antibody Linden P K, Angus D C, Chelluri L, Branch R (...) A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using human anti-endotoxin antibody (HA-1A) in patients with sepsis and suspicion of gram-negative bacteremia (GNB). Type of intervention Treatment. Economic study type Cost

1995 NHS Economic Evaluation Database.

419. Early-onset neonatal group B streptococcal sepsis: economics of various prevention strategies

Early-onset neonatal group B streptococcal sepsis: economics of various prevention strategies Early-onset neonatal group B streptococcal sepsis: economics of various prevention strategies Early-onset neonatal group B streptococcal sepsis: economics of various prevention strategies Garland S M, Kelly N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prevention strategies for early-onset neonatal group B streptococcal sepsis. Type of intervention Screening and primary prevention. Economic study type Cost-effectiveness analysis. Study population Pregnant women with and without obstetric risk factors. Setting The setting was hospital obstetric centres. Australian data were used where possible. Dates to which data relate

1995 NHS Economic Evaluation Database.

420. Corticosteroids treatment for sepsis: a critical appraisal and meta-analysis of the literature

Corticosteroids treatment for sepsis: a critical appraisal and meta-analysis of the literature PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

1995 PedsCCM Evidence-Based Journal Club